Covid-19 Research

Research Article

Beta-Chitosane as a Treatment for Ulcerative Colitis: Therapeutic Effectiveness and Possible Mechanisms of Action

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Research Article
Subject Biology Group
OCLC 9041188619
Laribi-Habchi Hassiba*, Laichi Yasmine, Saadoune Zineb, Boucherit Ahmed and Azine Kenza
Issue: Volume2-Issue3
Pages: 114-124
Received: 2021-02-20
Accepted: 2021-03-05
Published: 2021-03-06

Abstract

Purpose: Colitis is a widespread inflammatory bowel disease with heterogeneous etiology (genetic and immunological). It is treated with drugs such as steroidal and non-steroidal anti-inflammatory that, in the long term, can cause side effects. For this reason, the exploitation of natural resources to combat this type of disease is the concern of researchers. The purpose of our study was to evaluate the anti-colitis (anti-inflammatory) effect of β-Chitosane induced in albino mice by acetic acid (5%).

Methods: Mices were separated into six groups: the witness (untreated and not ulcerated), negative control group (ulcerated and untreated), the positive control ulcerated and treated with the Dexaméthasone® (1 mg/kg), and test groups ulcerated and treated with different doses of β-Chitosane (0.5 g/ kg; 0.75 g/ kg and 1 g/ kg) for the entire treatment estimated to six-days. β-Chitosane efficacy was evaluated by macroscopic and microscopic scores.

Results: The clinical scores showed that β-Chitosane with a dose of 1 g/kg for the entire treatment significantly reduced the damage caused by acetic acid with a score of (3.41 ± 1.45) compared to those of the positive control which reduced less the inflammation (6.26 ± 1.23). The histological study of the colons was able to validate the effect of β-Chitosane by decreasing neutrophil infiltration and ulceration in the colon as well as by structural recovery of the mucosa.

Conclusion: These results provide evidence that β-Chitosane has a protective effect against ulcerative colitis that may be due to its antioxidant, anti infectious, anti-inflammatory and healing activities.

FullText HTML FullText PDF DOI: 10.37871/jbres1199 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2021 Laribi-Habchi H, et al. Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Laribi-Habchi H, Yasmine L, Zineb S, Boucherit A, Kenza A. Beta-Chitosane as a Treatment for Ulcerative Colitis: Therapeutic Effectiveness and Possible Mechanisms of Action. J Biomed Res Environ Sci. 2021 Mar 06; 2(3): 114-124. doi: 10.37871/jbres1199, Article ID: jbres1199

Subject area(s)

BiomedicineGeneticsMicrobiologyBiotechnology

References

  1. Louis, et al, Génétique et environnement dans les maladies inflammatoires chroniques de l’intestin. Renue Médicale de Liège. 2012;67: 298-304.
  2. Park KT, Ehrlich OG, Allen JI, Meadows P, Szigethy EM, Henrichsen K, Kim SC, Lawton RC, Murphy SM, Regueiro M, Rubin DT, Engel-Nitz NM, Heller CA. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn’s & Colitis Foundation. Inflamm Bowel Dis. 2020 Jan 1;26(1):1-10. doi: 10.1093/ibd/izz104. Erratum in: Inflamm Bowel Dis. 2020 Jun 18;26(7):1118. PMID: 31112238; PMCID: PMC7534391.
  3. Frank DN, Robertson CE, Hamm CM, Kpadeh Z, Zhang T, Chen H, Zhu W, Sartor RB, Boedeker EC, Harpaz N, Pace NR, Li E. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis. 2011 Jan;17(1):179-84. doi: 10.1002/ibd.21339. Epub 2010 Sep 13. PMID: 20839241; PMCID: PMC3834564.
  4. Welcker, et al, Augmenntation de la perméabilité intestinale chez les patients atteints d’une maladie inflammatoire de l’intestin. European Journal of Medical Research. 2004;9:456-460.
  5. Pizarro TT, Cominelli F. Cytokine therapy for Crohn’s disease: advances in translational research. Annu Rev Med. 2007;58:433-44. doi: 10.1146/annurev.med.58.121205.100607. PMID: 17217333.
  6. Bouhnik Y, Manifestations extradigestives des maladies inflammatoires. 2006.
  7. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003 Jul;3(7):521-33. doi: 10.1038/nri1132. PMID: 12876555.
  8. Vidal A, Gómez-Gil E, Sans M, Portella MJ, Salamero M, Piqué JM, Panés J. Life events and inflammatory bowel disease relapse: a prospective study of patients enrolled in remission. Am J Gastroenterol. 2006 Apr;101(4):775-81. doi: 10.1111/j.1572-0241.2006.00476.x. Epub 2006 Feb 22. PMID: 16494590.
  9. Cortot A, et al. Inflammatory bowel disease: Genetir or environmental diseases? Gastroenterologie clinique et biologique. 2008;33(8-9):681-691.
  10. Sagheer A, et al. characterization of chintin and chitosan from marinesources in Arabian Gulf Carbohydrate. Polymers. 2009;77:410-419.
  11. Seng JM. Chitine, Chitosane et dérivés; de nouvelles perspectives pour l’industrie. Biofuture. 1988;9 :40‐44.
  12. Aimin C, Chunlin H, Juliang B, Tinyin Z, Zhichao D. Antibiotic loaded chitosan bar. An in vitro, in vivo study of a possible treatment for osteomyelitis. Clin Orthop Relat Res. 1999 Sep;(366):239-47. PMID: 10627741.
  13. No HK, Park NY, Lee SH, Meyers SP. Antibacterial activity of chitosans and chitosan oligomers with different molecular weights. Int J Food Microbiol. 2002 Mar 25;74(1-2):65-72. doi: 10.1016/s0168-1605(01)00717-6. PMID: 11929171.
  14. Jarmila V, Vavríková E. Chitosan derivatives with antimicrobial, antitumour and antioxidant activities--a review. Curr Pharm Des. 2011;17(32):3596-607. doi: 10.2174/138161211798194468. PMID: 22074429.
  15. Xianomin Wang, LZ, Tianzhao Han, Shaofei Chen, Jialing Wang. Protective effects of 2,3,5,4’ tetrahydroxystilbene -2-O-beta-D-glucoside, an active component of polygonum multiflorum Thumb, on experimental colitis in mice. European Journal of Pharmacology. 2008.
  16. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993 Aug;69(2):238-49. PMID: 8350599.
  17. Deshmukh CD, Pawar AT, Bantal V. Protective effect of Emblica officinalis fruits extract on acetic acid induced colitis in rats. Research Journal of Medicinal Plants. 2010;4(3):141-148. doi: 10.3923/rjmp.2010.141.148
  18. Sotnikova R, Nosalova V, Navarova J. Efficacy of quercetin derivatives in prevention of ulcerative colitis in rats. Interdiscip Toxicol. 2013 Mar;6(1):9-12. doi: 10.2478/intox-2013-0002. PMID: 24170973; PMCID: PMC3795315.
  19. Vllasaliu D, Exposito-Harris R, Heras A, Casettari L, Garnett M, Illum L, Stolnik S. Tight junction modulation by chitosan nanoparticles: comparison with chitosan solution. Int J Pharm. 2010 Nov 15;400(1-2):183-93. doi: 10.1016/j.ijpharm.2010.08.020. Epub 2010 Aug 19. PMID: 20727955.
  20. Lamprecht A, Schäfer U, Lehr CM. Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res. 2001 Jun;18(6):788-93. doi: 10.1023/a:1011032328064. PMID: 11474782.
  21. MARIO F. Systèmes multiparticules par voie orale dans les maladies inflammatoires chroniques de l’intestin. 2012.
  22. Briant J. Phénomènes d’interface agents de surface: Principes et modes d’action. 1989.
  23. Kaci G. Caractérisation des propriétés anti-inflammatoires de souches commensales de Streptococcus salivarius. Paris; 2012. p.11.
  24. Sadeghi AM, Dorkoosh FA, Avadi MR, Saadat P, Rafiee-Tehrani M, Junginger HE. Preparation, characterization and antibacterial activities of chitosan, N-Trimethyl Chitosan (TMC) and N-Diethylmethyl Chitosan (DEMC) nanoparticles loaded with insulin using both the ionotropic gelation and polyelectrolyte complexation mothods. International Journal of Pharmaceutics. 2007 Dec 4;355(1-2):299-306. doi: 10.1016/j.ijpharm.2007.11.052
  25. Qi L, Xu Z, Jiang X, Hu C, Zou X. Preparation and antibacterial activity of chitosan nanoparticles. Carbohydr Res. 2004 Nov 15;339(16):2693-700. doi: 10.1016/j.carres.2004.09.007. PMID: 15519328.
  26. Schulzke JD, Bojarski C, Zeissig S, Heller F, Gitter AH, Fromm M. Disrupted barrier function through epithelial cell apoptosis. Ann N Y Acad Sci. 2006 Aug;1072:288-99. doi: 10.1196/annals.1326.027. PMID: 17057208.
  27. Stevens ALBJ, Young. Anatomie pathologique. 4éme édition. de Boeck Supérieur; 2004. p.10-11.
  28. Yougbaré-Ziébrou, Ouédraogo N, Lompo M, Bationo H, Yaro B, Gnoula C, Sawadogo WR, Guissou IP. Anti-inflammatory, analgesic and antioxidant activities of an aqueous extract of Saba senegalensis Pichon stems with leaves (Apocynaceae) Pharmacognosie. 2015 October 4;14:213-219. doi : 10.1007/s10298-015-0992-5
  29. Topcu-Tarladacalisir Y, Akpolat M, Uz YH, Kizilay G, Sapmaz-Metin M, Cerkezkayabekir A, Omurlu IK. Effects of curcumin on apoptosis and oxidoinflammatory regulation in a rat model of acetic acid-induced colitis: the roles of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase. J Med Food. 2013 Apr;16(4):296-305. doi: 10.1089/jmf.2012.2550. PMID: 23566056.
  30. Zeng C, Xiao JH, Chang MJ, Wang JL. Beneficial effects of THSG on acetic acid-induced experimental colitis: involvement of upregulation of PPAR-γ and inhibition of the Nf-Κb inflammatory pathway. Molecules. 2011 Oct 12;16(10):8552-68. doi: 10.3390/molecules16108552. PMID: 21993246; PMCID: PMC6264228.
  31. Otari KV, Gaikwad PS, Shete RV, Upasani CD. Protective effect of aqueous extract of Spinacia oleracea leaves in experimental paradigms of inflammatory bowel disease. Inflammopharmacology. 2012 Oct;20(5):277-87. doi: 10.1007/s10787-011-0114-4. Epub 2012 Jan 11. PMID: 22234676.
  32. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology. 1995 Oct;109(4):1344-67. doi: 10.1016/0016-5085(95)90599-5. PMID: 7557106.
  33. Touboul J. Diarrhée de l’épisode aigu infectieux au trouble foncionnel chronique. Actuelitéhérapeutique. 2007;10:164-167.
  34. V VP, C G. Protective effect of marine mangrove Rhizophora apiculata on acetic acid induced experimental colitis by regulating anti-oxidant enzymes, inflammatory mediators and nuclear factor-kappa B subunits. Int Immunopharmacol. 2014 Jan;18(1):124-34. doi: 10.1016/j.intimp.2013.11.007. Epub 2013 Nov 21. PMID: 24269623.
  35. Bounihi, Criblage phytochimique, Étude Toxicologique et Valorisation Pharmacologique de Melissa officinalis et de Mentha rotundifolia (Lamiacées). Thèse de Doctorat de Sciences du Médicament. 2016.
  36. Elodie Q, Philippe S. Intestinal microbiota: From antibiotic-associated diarrhea to inflammatory bowel diseases. La Presse Médicale. 2012 January;42(1):45-51. doi : 10.1016/j.lpm.2012.09.017
  37. Lee A, De Mei C, Fereira M, Marotta R, Yoon HY, Kim K, Kwon IC, Decuzzi P. Dexamethasone-loaded Polymeric Nanoconstructs for Monitoring and Treating Inflammatory Bowel Disease. Theranostics. 2017 Aug 23;7(15):3653-3666. doi: 10.7150/thno.18183. PMID: 29109767; PMCID: PMC5667339.
  38. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med. 2005 Oct 20;353(16):1711-23. doi: 10.1056/NEJMra050541. PMID: 16236742.
  39. Yousef M, Pichyangkura R, Soodvilai S, Chatsudthipong V, Muanprasat C. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action. Pharmacol Res. 2012 Jul;66(1):66-79. doi: 10.1016/j.phrs.2012.03.013. Epub 2012 Mar 28. PMID: 22475725.
  40. Jain SK, Jain A, Gupta Y, Ahirwar M. Design and development of hydrogel beads for targeted drug delivery to the colon. AAPS PharmSciTech. 2007 Jul 13;8(3):E56. doi: 10.1208/pt0803056. PMID: 17915806; PMCID: PMC2750443.
  41. Zhang H, Neau SH. In vitro degradation of chitosan by bacterial enzymes from rat cecal and colonic contents. Biomaterials. 2002 Jul;23(13):2761-6. doi: 10.1016/s0142-9612(02)00011-x. PMID: 12059026.
  42. Gulbake A, Jain SK. Chitosan: a potential polymer for colon-specific drug delivery system. Expert Opin Drug Deliv. 2012 Jun;9(6):713-29. doi: 10.1517/17425247.2012.682148. Epub 2012 Apr 24. PMID: 22530707.
  43. Azuma K, Izumi R, Osaki T, Ifuku S, Morimoto M, Saimoto H, Minami S, Okamoto Y. Chitin, chitosan, and its derivatives for wound healing: old and new materials. J Funct Biomater. 2015 Mar 13;6(1):104-42. doi: 10.3390/jfb6010104. Retraction in: J Funct Biomater. 2018 Jun 07;9(2): PMID: 25780874; PMCID: PMC4384104.
  44. Zheng LY, Zhu JF. Study on antimictobial activity of chitosan with different molecular weights. Carbohydr Polym. 2003;54(4):527-530. Doi : 10.1016/j.carbpol.2003.07.009
  45. Benbbou, R. Developpment Et Caracterisation De Films Antimicrobiens Pour La Biopréservation Des Produits Marins Prêts À Consommer. 2009.
  46. Qiao Y, et al. Synergistic Activation of inflammatory Cytokine Gene by interferon-g-induced Chromatin Remodeling and Toll-like receptor signaling, USA 5Graduate Program in Immunology and Microbial Pathogenesis, Weill Cornell Graduate School of Medical Sciences, New York, NY 10065, USA.
  47. Chou TC, Fu E, Shen EC. Chitosan inhibits prostaglandin E2 formation and cyclooxygenase-2 induction in lipopolysaccharide-treated RAW 264.7 macrophages. Biochem Biophys Res Commun. 2003 Aug 22;308(2):403-7. doi: 10.1016/s0006-291x(03)01407-4. PMID: 12901883.
  48. Citgez B, Cengiz AN, Akgun I, Uludag M, Yetkin G, Bahat N, Ozcan O, Polat N, Akcakaya A, Karatepe O. Effects of chitosan on healing and strength of colonic anastomosis in rats. Acta Cir Bras. 2012 Oct;27(10):707-12. doi: 10.1590/s0102-86502012001000007. PMID: 23033132.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership